The European Cancer Concord® (ECC) was established in 2013 under the stewardship and funding* from the Society for Translational Oncology® (STO).

The ECC consists of a group of European cancer patients, patient advocates and professionals, working in partnership to improve outcomes for European cancer patients.

We seek to catalyse change by working in an innovative, supportive and collaborative way with the many organisations which strive to improve cancer outcomes at the European and national level.  

To find out more about the ECC, please click here.


Bill of Rights

The ECC has created a "European Cancer Patient’s Bill of Rights", a patient charter that underpins equitable access to optimal cancer control and research for Europe’s citizens. This was launched at the European Parliament and endorsed by the EC Health Commissioner on World Cancer Day 2014. An updated version of the Bill of Rights and its strategic implementation was presented at two meetings on World Cancer Day 2016, in Brussels and Strasbourg.

Three patient-centred principles underpin the European Cancer Patient’s Bill of Rights:

European Cancer Patient’s Bill of Rights



Click here to find out more about the Bill of Rights.

*We gratefully acknowledge the funding provided to STO which has been deployed to support the work of the ECC. STO received generous grant support and contributions in kind from AlphaMed Cancer Foundation, Hogan Lovells, Bristol-Myers Squibb Foundation, Sanofi and Bayer along with the pro bono contributions of advocates and the patients they passionately represent.



The European Cancer Patient’s Bill of Rights has been awarded the prestigious 2018 European Health Award.

European Cancer Concord Meeting 27th January 2017

A European Cancer Concord meeting was held on Friday 27th January 2017, co-located with the ECCO Congress in Amsterdam.

The aim of the meeting was to consult specifically with the patients and patient advocates on the strategy of the ECC, and our plans for the future.